Health Secretary Robert F. Kennedy Jr. endorsed the expanded use of RSV vaccines for people 50 through 59 years old who are ...

The new vaccine committee appointed by Secretary Robert F. Kennedy Jr. took minimal action in its first meeting.

A new study from the University of Oxford has revealed a surprising benefit of the respiratory syncytial virus (RSV) vaccine: ...

Merck & Co., Inc. (NYSE: MRK) is one of the. The company announced that the US FDA approved ENFLONSIA™ (clesrovimab-cfor) for ...

The new RSV recommendation calls for a single dose of vaccine for adults age 50 to 59 years who are at increased risk of ...

The expanded recommendation is good news for Moderna, Pfizer, and GSK, which all sell RSV vaccines for older adults. Moderna ...

The U.S. Centers for Disease Control and Prevention has accepted recommendations made by a panel of vaccine experts in April, ...

The Trump administration appears to be expanding RSV vaccinations to some adults starting at age 50 instead of 60 ...

The monoclonal antibody nirsevimab, though not a vaccine, is approved by the FDA for the prevention of RSV lower respiratory tract disease in newborns and infants born during or entering their ...

The federal Vaccine Adverse Event Reporting System recorded about 10.6 million adults ages 60 years and older receiving a recommended RSV vaccine between August 4, 2023 and March 30, 2024.

I highly recommend the RSV vaccine. Although no vaccine prevents illness 100% of the time, if you are vaccinated and still get RSV, you are much more likely to have a mild case of the illness.